Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,179 shares of the biotechnology company’s stock after purchasing an additional 64,101 shares during the quarter. Barclays PLC’s holdings in Anavex Life Sciences were worth $882,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Nwam LLC purchased a new stake in Anavex Life Sciences in the third quarter valued at $5,172,000. Charles Schwab Investment Management Inc. raised its position in Anavex Life Sciences by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 14,892 shares during the period. Renaissance Technologies LLC raised its position in Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 386,537 shares during the period. Bank of New York Mellon Corp raised its position in Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after purchasing an additional 40,895 shares during the period. Finally, Rhumbline Advisers raised its position in Anavex Life Sciences by 15.8% in the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 16,293 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 8.8 %

AVXL stock opened at $11.04 on Tuesday. The company has a market capitalization of $936.37 million, a PE ratio of -22.08 and a beta of 0.73. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44. The business’s fifty day moving average price is $8.29 and its 200 day moving average price is $6.46.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Research analysts predict that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

AVXL has been the topic of a number of research analyst reports. HC Wainwright lifted their target price on Anavex Life Sciences from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, December 26th. D. Boral Capital restated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, December 23rd.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.